Vancouver, British Columbia – TheNewswire - August 6, 2025 – MindBio Therapeutics Corp . (CSE: MBIO; Frankfurt: WF6) (“MindBio” or the “Company”), a clinical-stage biopharmaceutical company focused on novel treatments for depressive disorders, is pleased to provide an update on clinical trials and corporate activity. The Company is in the completion stages of testing its lead candidate drug MB22001, in a Phase 2B trial in... Read More